Harrow, Inc. (HROW) Q2 2026 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Harrow, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.091 -- 00:00:06.013 Good morning and welcome to HERO's second quarter 2026 earnings conference call. 00:00:06.013 -- 00:00:10.534 My name is Michelle and I will be the operator for today's call. 00:00:10.534 -- 00:00:14.675 At this time, all participants are in a listen-only mode. 00:00:14.675 -- 00:00:18.876 Later, we will conduct a question and answer session. 00:00:18.876 -- 00:00:22.277 As a reminder, this conference is being recorded. 00:00:22.277 -- 00:00:27.699 I would now like to turn the conference over to Mike Biega, Vice President 00:00:27.699 -- 00:00:31.607 of Investor Relations and Communications for HARO. 00:00:31.607 -- 00:00:34.287 Please go ahead. 00:00:35.789 -- 00:00:40.671 Thank you, operator. Good morning and welcome to HARO's second quarter 2026 earnings 00:00:40.671 -- 00:00:45.913 conference call. My name is Mike Biega, Vice President of Investor Relations and Communications, 00:00:45.913 -- 00:00:48.795 and I'm excited to be introducing today's call. 00:00:48.795 -- 00:00:52.797 The company's remarks may include forward-looking statements within the meaning of federal 00:00:52.797 -- 00:00:54.914 securities laws. 00:00:54.914 -- 00:01:00.078 are subject to numerous risks and uncertainties, many of which are beyond Harold's control, 00:01:00.078 -- 00:01:05.002 including risks and uncertainties described from time to time in its SEC filings, such 00:01:05.002 -- 00:01:08.766 as the risks and uncertainties related to the company's ability to make commercially 00:01:08.766 -- 00:01:13.810 available its FDA-approved products and compounded formulations and technologies and 00:01:13.810 -- 00:01:18.280 FDA approval of certain drug candidates in a timely manner or at all. 00:01:18.280 -- 00:01:22.542 For a list and description of t...